Gain Therapeutics Analyst Ratings
Gain Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/12/2023 | 158.06% | Maxim Group | → $10 | Initiates Coverage On | → Buy |
| 08/31/2023 | 158.06% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 08/14/2023 | 54.84% | Chardan Capital | → $6 | Reiterates | Buy → Buy |
| 08/14/2023 | 158.06% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 06/12/2023 | 158.06% | Oppenheimer | → $10 | Reiterates | Outperform → Outperform |
| 05/15/2023 | 158.06% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 05/15/2023 | 54.84% | Chardan Capital | $5.75 → $6 | Maintains | Buy |
| 05/01/2023 | 158.06% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 03/27/2023 | 48.39% | Chardan Capital | $4 → $5.75 | Maintains | Buy |
| 12/09/2022 | 3.23% | Chardan Capital | → $4 | Initiates Coverage On | → Buy |
| 11/25/2022 | 158.06% | Oppenheimer | $30 → $10 | Maintains | Outperform |
| 11/14/2022 | 158.06% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 11/14/2022 | 158.06% | BTIG | $30 → $10 | Maintains | Buy |
| 08/19/2022 | 29.03% | B. Riley Securities | $11 → $5 | Downgrades | Buy → Neutral |
| 03/29/2022 | 312.9% | B. Riley Securities | $21 → $16 | Maintains | Buy |
| 03/29/2022 | 209.68% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 11/03/2021 | 441.94% | B. Riley Securities | → $21 | Initiates Coverage On | → Buy |
| 04/12/2021 | 674.19% | Oppenheimer | → $30 | Initiates Coverage On | → Outperform |
| 04/12/2021 | 674.19% | BTIG | → $30 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/12/2023 | 158.06% | Maxim集團 | →$10 | 開始承保 | →購買 |
| 2023年08月31日 | 158.06% | HC Wainwright公司 | →$10 | 重申 | 購買→購買 |
| 2023年08月14日 | 54.84% | 查爾丹資本 | →$6 | 重申 | 購買→購買 |
| 2023年08月14日 | 158.06% | HC Wainwright公司 | →$10 | 重申 | 購買→購買 |
| 2023/06/12 | 158.06% | 奧本海默 | →$10 | 重申 | 跑贏→跑贏大盤 |
| 2023年05月15日 | 158.06% | HC Wainwright公司 | →$10 | 重申 | 購買→購買 |
| 2023年05月15日 | 54.84% | 查爾丹資本 | $5.75→$6 | 維護 | 買 |
| 05/01/2023 | 158.06% | HC Wainwright公司 | →$10 | 重申 | →購買 |
| 03/27/2023 | 48.39% | 查爾丹資本 | $4→$5.75 | 維護 | 買 |
| 12/09/2022 | 3.23% | 查爾丹資本 | →$4 | 開始承保 | →購買 |
| 2022年11月25日 | 158.06% | 奧本海默 | $30→$10 | 維護 | 跑贏大盤 |
| 2022年11月14日 | 158.06% | HC Wainwright公司 | $12→$10 | 維護 | 買 |
| 2022年11月14日 | 158.06% | BTIG | $30→$10 | 維護 | 買 |
| 2022年08月19日 | 29.03% | B.萊利證券 | $11→$5 | 評級下調 | 購買→中性 |
| 03/29/2022 | 312.9% | B.萊利證券 | $21→$16 | 維護 | 買 |
| 03/29/2022 | 209.68% | HC Wainwright公司 | →$12 | 開始承保 | →購買 |
| 11/03/2021 | 441.94% | B.萊利證券 | →$21 | 開始承保 | →購買 |
| 04/12/2021 | 674.19% | 奧本海默 | →$30 | 開始承保 | →跑贏大盤 |
| 04/12/2021 | 674.19% | BTIG | →$30 | 開始承保 | →購買 |
What is the target price for Gain Therapeutics (GANX)?
Gain Treeutics(GANX)的目標價格是多少？
The latest price target for Gain Therapeutics (NASDAQ: GANX) was reported by Maxim Group on September 12, 2023. The analyst firm set a price target for $10.00 expecting GANX to rise to within 12 months (a possible 158.06% upside). 13 analyst firms have reported ratings in the last year.
MAXIM集團於2023年9月12日報道了Gain治療公司(納斯達克代碼：GANX)的最新目標價。這家分析公司將目標價定為10美元，預計GANX將在12個月內上漲(可能上漲158.06%)。過去一年，有13家分析公司公佈了評級。
What is the most recent analyst rating for Gain Therapeutics (GANX)?
Gain Treeutics(GANX)的最新分析師評級是多少？
The latest analyst rating for Gain Therapeutics (NASDAQ: GANX) was provided by Maxim Group, and Gain Therapeutics initiated their buy rating.
Gain治療公司(納斯達克代碼：GANX)的最新分析師評級由Maxim Group提供，Gain治療公司啟動了他們的買入評級。
When is the next analyst rating going to be posted or updated for Gain Therapeutics (GANX)?
Gain Treeutics(GANX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gain Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gain Therapeutics was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Gain Treeutics的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Gain治療公司的上一次評級是在2023年9月12日提交的，所以你應該預計下一次評級將在2024年9月12日左右提供。
Is the Analyst Rating Gain Therapeutics (GANX) correct?
分析師評級增益治療公司(GANX)正確嗎？
While ratings are subjective and will change, the latest Gain Therapeutics (GANX) rating was a initiated with a price target of $0.00 to $10.00. The current price Gain Therapeutics (GANX) is trading at is $3.88, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Gain Treeutics(GANX)評級是以0.00美元至10.00美元的目標價啟動的。目前的價格上漲治療(GANX)的交易價格為3.88美元，這在分析師的預測範圍內。